Key result
A community pharmacy-based pharmacogenetic management service for 30 post-myocardial infarction patients resulted in 8 recommendations (26.7%) for antiplatelet therapy adjustment.
Why the study?
Can community pharmacists successfully implement a pharmacogenetic management service to guide antiplatelet therapy adjustments in post-myocardial infarction patients?
Can community pharmacists successfully implement a pharmacogenetic management service to guide antiplatelet therapy adjustments in post-myocardial infarction patients?
Community pharmacists can successfully implement pharmacogenetic testing to facilitate antiplatelet therapy adjustments in post-myocardial infarction patients, extending this service beyond the inpatient setting.
Supports community pharmacist-led pharmacogenetic services for post-MI antiplatelet adjustment; extends inpatient models to outpatient settings.
AIM: The purpose of this study was to pilot a multisite, proof-of-concept model where community pharmacists could engage patients and physicians to provide pharmacogenetic (PGt) testing and clinical decision support. PATIENTS & METHODS: Patients with history of acute myocardial infarction and percutaneous coronary intervention with no prior history of CYP2C19 testing. RESULTS: Four community pharmacies provided pharmacogenetic testing and medication therapy management services to 30 patients, resulting in eight recommendations for antiplatelet therapy adjustment. CONCLUSION: Pharmacists involved in the study were able to facilitate antiplatelet therapy adjustments based on PGt data regardless of baseline antiplatelet drug selection. Whereas prior literature largely revolved around PGt management in the inpatient setting, this project supports the involvement of the community pharmacist in making PGt-based recommendations.
No takes yet. Share an insight, caveat, or question.
Bright et al. (2015) studied Post-myocardial infarction (n=30). Pharmacogenetic (PGt) testing and clinical decision support was evaluated on Recommendations for antiplatelet therapy adjustment. A community pharmacy-based pharmacogenetic management service for 30 post-myocardial infarction patients resulted in 8 recommendations (26.7%) for antiplatelet therapy adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: